Related Experiment Video
Updated: Aug 24, 2025
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
The interplay between MMP-12 and t-PA in the brain after ischemic stroke
Siva Reddy Challa1, Koteswara Rao Nalamolu2, Casimir A Fornal2
1Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA; Department of Pharmacology, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Matrix metalloproteinase-12 (MMP-12) and tissue-type plasminogen activator (t-PA) interact in the brain after ischemic stroke. Suppressing t-PA reduces MMP-12, protects the blood-brain barrier, and lessens neuroinflammation, offering potential stroke therapies.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Tissue-type plasminogen activator (t-PA) and matrix metalloproteinase-12 (MMP-12) are implicated in ischemic stroke.
- Previous studies suggested MMP-12 influences t-PA expression after cerebral ischemia.
Purpose of the Study:
- To investigate the temporal expression of t-PA in the brain post-ischemia.
- To elucidate the interaction between MMP-12 and t-PA in ischemic stroke.
- To determine the therapeutic potential of targeting these proteases.
Main Methods:
- Transient focal cerebral ischemia and reperfusion in a rat model.
- shRNA-mediated gene silencing of t-PA.
- Assessment of blood-brain barrier (BBB) integrity and tight junction proteins (claudin-5).
- Analysis of neuroinflammation markers (CD68, iNOS, IL-1β, TNFα).
- Computational modeling for protein-protein interactions.
Main Results:
- Suppression of t-PA led to decreased MMP-12 expression in the brain.
- t-PA suppression attenuated claudin-5 degradation and reduced BBB disruption.
- Reduced neuroinflammation was observed, with decreased M1 phenotype markers.
- Computational modeling suggested a physical interaction between MMP-12 and t-PA.
Conclusions:
- MMP-12 and t-PA exhibit reciprocal interactions in the brain following ischemic stroke.
- Targeting t-PA may mitigate BBB damage and neuroinflammation.
- These findings support the development of novel stroke pharmacotherapies.
